Gaëlle Pierron - Genetic Mutations

Author Information

Gaëlle Pierron is affiliated with the Unit of Somatic Genetics at Institut Curie in Paris, France. Her research primarily focuses on pediatric cancers, particularly involving genetic and molecular analyses of various tumor types. Her contributions have significantly advanced the understanding of cancer genomics and precision medicine, especially in young patients.

Research Contributions

Gaëlle Pierron has made substantial contributions to the field of pediatric oncology through her extensive research on the genetic and molecular characteristics of cancers affecting children, adolescents, and young adults. Some of her notable works include studies on NUT carcinoma, CNS high-grade neuroepithelial tumors, liver metastatic uveal melanoma, and various other pediatric malignancies. Her research often emphasizes the importance of precision medicine and the potential benefits of new targeted therapies. Her recent publications have explored multimodal analysis of cell-free DNA, the clinical features of inflammatory myofibroblastic tumors, and diagnostic biomarkers for CNS tumors with BCOR internal tandem duplication.

Aliases

Gaëlle Pierron is also known by the following aliases: Gaelle Pierron, G Pierron, Gäelle Pierron, G. Pierron, and G. Pierron.

Publication and Citation Metrics

Metric	Value
Citation Count	10089
h-index	53
Paper Count	262

Publications:

NUT carcinoma in children, adolescents and young adults.

DOI: 10.1016/j.bulcan.2022.01.015

Year: 2022

Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a BCOR Internal Tandem Duplication

DOI: 10.3174/ajnr.A7367

Year: 2022

Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.

DOI: 10.1038/s41416-022-01793-8

Year: 2022

The European MAPPYACTS trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.

DOI: 10.1158/2159-8290.CD-21-1136

Year: 2022

Potential Benefit of New Target Inhibitors in Neurotrophic Tropomyosin Receptor Kinase Fusion Positive Tumors: A Historical Cohort Analysis

DOI: 10.2139/ssrn.4083736

Year: 2022

Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden

DOI: 10.1038/s41467-021-23445-w

Year: 2021

Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents

DOI: 10.1002/pbc.29460

Year: 2021

BCOR immunohistochemistry, but not SATB2 immunohistochemistry, is a sensitive and specific diagnostic biomarker for central nervous system tumours with BCOR internal tandem duplication

DOI: 10.1111/his.14439

Year: 2021

Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease: A Study of 4 Aggressive Cases With Clinical, Pathologic, Molecular, and Radiologic Findings.

DOI: 10.1097/PAS.0000000000001702

Year: 2021

Pineal alveolar rhabdomyosarcoma with PAX3:NCOA2 fusion inducing OLIG2 expression, a potential pitfall in the central nervous system

DOI: 10.1111/his.14364

Year: 2021

What are inherited genetic mutations?

How Do These Tools Improve Diagnosis?

What is Polymerase Chain Reaction (PCR)?

What are the Challenges Associated with TKIs?

How Do Deletion Mutations Occur?

Can Genetic Testing Help in Identifying Asbestos-Related Risks?

Who Should Consider Prenatal Screening and Genetic Counseling?

What are the Options for Individuals with BRCA1 or BRCA2 Mutations?

What Are the Consequences of Meiosis Errors?

How is Cancer Genomics Studied?

Partnered Content Networks

Relevant Topics